Anand Rohatgi1, Amit Khera, Jarett D Berry, Edward G Givens, Colby R Ayers, Kyle E Wedin, Ian J Neeland, Ivan S Yuhanna, Daniel R Rader, James A de Lemos, Philip W Shaul. 1. From the Division of Cardiology, Department of Internal Medicine (A.R., A.K., J.D.B., E.G.G., C.R.A., I.J.N., J.A.L.), and the Center for Pulmonary and Vascular Biology, Department of Pediatrics (I.S.Y., P.W.S.), University of Texas Southwestern Medical Center, Dallas; the Department of Internal Medicine, Emory University, Atlanta (K.E.W.); and the Departments of Genetics and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.R.R.).
Abstract
BACKGROUND: It is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport. We investigated the epidemiology of cholesterol efflux capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a large, multiethnic population cohort. METHODS: We measured HDL cholesterol level, HDL particle concentration, and cholesterol efflux capacity at baseline in 2924 adults free from cardiovascular disease who were participants in the Dallas Heart Study, a probability-based population sample. The primary end point was atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular causes. The median follow-up period was 9.4 years. RESULTS: In contrast to HDL cholesterol level, which was associated with multiple traditional risk factors and metabolic variables, cholesterol efflux capacity had minimal association with these factors. Baseline HDL cholesterol level was not associated with cardiovascular events in an adjusted analysis (hazard ratio, 1.08; 95% confidence interval [CI], 0.59 to 1.99). In a fully adjusted model that included traditional risk factors, HDL cholesterol level, and HDL particle concentration, there was a 67% reduction in cardiovascular risk in the highest quartile of cholesterol efflux capacity versus the lowest quartile (hazard ratio, 0.33; 95% CI, 0.19 to 0.55). Adding cholesterol efflux capacity to traditional risk factors was associated with improvement in discrimination and reclassification indexes. CONCLUSIONS: Cholesterol efflux capacity, a new biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events in a population-based cohort. (Funded by the Donald W. Reynolds Foundation and others.).
BACKGROUND: It is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport. We investigated the epidemiology of cholesterol efflux capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a large, multiethnic population cohort. METHODS: We measured HDL cholesterol level, HDL particle concentration, and cholesterol efflux capacity at baseline in 2924 adults free from cardiovascular disease who were participants in the Dallas Heart Study, a probability-based population sample. The primary end point was atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular causes. The median follow-up period was 9.4 years. RESULTS: In contrast to HDL cholesterol level, which was associated with multiple traditional risk factors and metabolic variables, cholesterol efflux capacity had minimal association with these factors. Baseline HDL cholesterol level was not associated with cardiovascular events in an adjusted analysis (hazard ratio, 1.08; 95% confidence interval [CI], 0.59 to 1.99). In a fully adjusted model that included traditional risk factors, HDL cholesterol level, and HDL particle concentration, there was a 67% reduction in cardiovascular risk in the highest quartile of cholesterol efflux capacity versus the lowest quartile (hazard ratio, 0.33; 95% CI, 0.19 to 0.55). Adding cholesterol efflux capacity to traditional risk factors was associated with improvement in discrimination and reclassification indexes. CONCLUSIONS:Cholesterol efflux capacity, a new biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events in a population-based cohort. (Funded by the Donald W. Reynolds Foundation and others.).
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Angel Baldán; Liming Pei; Richard Lee; Paul Tarr; Rajendra K Tangirala; Michael M Weinstein; Joy Frank; Andrew C Li; Peter Tontonoz; Peter A Edwards Journal: Arterioscler Thromb Vasc Biol Date: 2006-08-03 Impact factor: 8.311
Authors: Chatchawin Assanasen; Chieko Mineo; Divya Seetharam; Ivan S Yuhanna; Yves L Marcel; Margery A Connelly; David L Williams; Margarita de la Llera-Moya; Philip W Shaul; David L Silver Journal: J Clin Invest Date: 2005-03-24 Impact factor: 14.808
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Tulika Jain; Ronald Peshock; Darren K McGuire; DuWayne Willett; Zhoaxia Yu; Zhoazia Yu; Gloria L Vega; Rudy Guerra; Helen H Hobbs; Scott M Grundy Journal: J Am Coll Cardiol Date: 2004-09-01 Impact factor: 24.094
Authors: Ronald G Victor; Robert W Haley; DuWayne L Willett; Ronald M Peshock; Patrice C Vaeth; David Leonard; Mujeeb Basit; Richard S Cooper; Vincent G Iannacchione; Wendy A Visscher; Jennifer M Staab; Helen H Hobbs Journal: Am J Cardiol Date: 2004-06-15 Impact factor: 2.778
Authors: Mark S Borja; Kit F Ng; Angela Irwin; Jaekyoung Hong; Xing Wu; Daniel Isquith; Xue-Qiao Zhao; Bryan Prazen; Virginia Gildengorin; Michael N Oda; Tomáš Vaisar Journal: J Lipid Res Date: 2015-08-07 Impact factor: 5.922
Authors: Samar R El Khoudary; Patrick M Hutchins; Karen A Matthews; Maria M Brooks; Trevor J Orchard; Graziella E Ronsein; Jay W Heinecke Journal: J Clin Endocrinol Metab Date: 2016-07-11 Impact factor: 5.958
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Robin P F Dullaart; Jan-Stephan F Sanders; Stephan J L Bakker; Uwe J F Tietge Journal: J Am Soc Nephrol Date: 2015-08-28 Impact factor: 10.121
Authors: Samar R El Khoudary; Lin Wang; Maria M Brooks; Rebecca C Thurston; Carol A Derby; Karen A Matthews Journal: J Clin Lipidol Date: 2016-04-26 Impact factor: 4.766
Authors: Shahzad Chindhy; Parag Joshi; Amit Khera; Colby R Ayers; S Susan Hedayati; Anand Rohatgi Journal: J Am Coll Cardiol Date: 2018-08-07 Impact factor: 24.094